The Experts below are selected from a list of 360 Experts worldwide ranked by ideXlab platform

Hideoki Ogawa - One of the best experts on this subject based on the ideXlab platform.

  • a comparative clinical study between 2 weeks of luliconazole 1 cream treatment and 4 weeks of bifonazole 1 cream treatment for Tinea pedis
    Mycoses, 2006
    Co-Authors: Shinichi Watanabe, Hideyo Yamaguchi, Hisashi Takahashi, Takeji Nishikawa, Iwao Takiuchi, Nobuhiko Higashi, Katsutaro Nishimoto, Saburo Kagawa, Hideoki Ogawa
    Abstract:

    The aim of the study was to compare the efficacy and safety of luliconazole 1% cream and bifonazole 1% cream as applied in the treatment of Tinea pedis (interdigital-type and plantar-type). A multi-clinic, randomised single-blind, parallel group study with 34 hospitals and 11 clinics formed the study design. Five hundred and eleven patients with mycologically confirmed Tinea pedis were included. Of the 489 evaluable patients, 247 were randomised to luliconazole, and 242 to bifonazole. Luliconazole 1% cream applied once a day for 2 weeks, followed by a placebo cream for 2 weeks, thereafter. Bifonazole 1% cream applied once a day for 4 weeks. Mycological effect (negative result on microscopy) and improvement of skin lesions were measured at weeks 1, 2, 3 and 4. Safety frequency and severity of adverse reactions were also measured. The improvement of skin lesions after 4 weeks was comparably good with rates of 91.5% vs. 91.7% (luliconazole vs. bifonazole). The mycological effect was characterised by high negative rates of 76.1% vs. 75.9% (luliconazole vs. bifonazole). The progression of Tinea-related signs and symptom scores differed insignificantly between evaluated luliconazole and bifonazole treatment groups comprising a total of 500 patients. Both substances appeared to be comparably safe and well-tolerated.

  • Clinical and mycological study of occult Tinea pedis and Tinea unguium in dermatological patients from Tokyo.
    Mycoses, 2003
    Co-Authors: Y. Ogasawara, Masataro Hiruma, Masahiko Muto, Hideoki Ogawa
    Abstract:

    Summary An epidemiological investigation was conducted to determine the prevalence and circumstances of untreated, unsuspected Tinea pedis and Tinea unguium, morbid conditions that could be termed occult athlete's foot, in patients visiting a dermatology clinic in Tokyo, Japan, for the first time, for other complaints. All subjects completed a questionnaire covering comprehensive anamnestic details, and were examined for disposition of toes, presence of signs suggestive of Tinea pedis, other diseases of the foot, score of clinical signs and symptoms, potassium hydroxide (KOH) test, severity score, and mycological culture. The results showed that the prevalence of occult athlete's foot was 25%, and that 59% of those cases were complicated by Tinea unguium. The characteristics of patients with occult athlete's foot included a higher proportion of men and a tendency toward a low clinical score together with a high severity score. In the patient background, a strong correlation was observed between a positive KOH test result and characteristics such as age, disposition of toes, and predisposing disease. Zusammenfassung Ambulante Patienten, die wegen anderer Beschwerden erstmals eine Hautklinik in Tokyo aufgesuchten, wurden auf vermutete, aber unbehandelte Tinea pedis und Tinea unguium untersucht (okkulte Tinea pedis et unguium). Von allen Patienten wurden umfassende anamnestische Erhebungen protokolliert, die Schwere des Tinea-Befalls beurteilt und mykologische Kulturen angelegt. Die Pravalenz okkulter Tinea pedis betrug 25%, davon waren 59% durch Tinea unguium kompliziert. Der Befund trat bei Mannern haufiger auf. Beziehungen zum Lebensalter und pradisponierenden Krankheiten wurden aufgedeckt.

Boni E. Elewski - One of the best experts on this subject based on the ideXlab platform.

  • econazole nitrate foam 1 for the treatment of Tinea pedis results from two double blind vehicle controlled phase 3 clinical trials
    Journal of Drugs in Dermatology, 2014
    Co-Authors: Boni E. Elewski, Tracey C Vlahovic
    Abstract:

    Background Econazole nitrate is a broad-spectrum topical antifungal with activity against a variety of dermatophytes and yeasts. A new topical dosage form, econazole nitrate topical foam 1%, utilizing patented Proderm Technology® has been developed for treatment of interdigital Tinea pedis. Objective To evaluate econazole nitrate foam 1% versus foam vehicle for treatment of interdigital Tinea pedis. Methods Two randomized, double-blind, parallel-group, vehicle-controlled, multicenter studies enrolled males and females ≥12 years old with a clinical diagnosis of interdigital Tinea pedis and baseline fungal culture positive for a dermatophyte. Subjects applied econazole nitrate foam 1% (n=246) or foam vehicle (n=249) once daily for 4 weeks. The primary endpoint was proportion of subjects achieving a complete cure (negative KOH, negative fungal culture, complete resolution of all signs and symptoms) at 2 weeks post-treatment (Day 43). Secondary endpoints included mycologic cure (negative KOH and negative culture) and effective treatment (mycologic cure + no or mild erythema and/or scaling and all other signs and symptoms absent). Results The complete cure rate at Day 43 was 24.3% for econazole nitrate foam 1% vs 3.6% for foam vehicle. In addition, higher rates of mycologic cure (67.6% vs 16.9%) and effective treatment (48.6% vs 10.8%) were observed with econazole nitrate foam 1% versus the foam vehicle. There were few adverse events and only nasopharyngitis and headache were experienced by >1% of subjects. No serious adverse events were reported for econazole nitrate foam 1%. Conclusions Econazole nitrate foam 1% exhibited superiority over foam vehicle for the primary and secondary endpoints with a high mycologic cure rate for all pathogens evaluated. Econazole nitrate foam 1% was safe and well tolerated with a safety profile comparable with the foam vehicle. Econazole nitrate foam 1% presents a novel alternative for the management of Tinea pedis.

  • efficacy and safety of terbinafine 1 solution in the treatment of interdigital Tinea pedis and Tinea corporis or Tinea cruris
    Cutis, 2001
    Co-Authors: Mark Lebwohl, Drore Eisen, Boni E. Elewski, Ronald C Savin
    Abstract:

    : Two randomized, double-blind, vehicle-controlled, multicenter studies assessed the efficacy and safety of a new terbinafine 1% solution for the treatment of interdigital Tinea pedis and Tinea corporis or Tinea cruris (Tinea corporis/cruris). Patients with interdigital Tinea pedis applied terbinafine 1% solution or vehicle twice daily for 1 week with 7 weeks of follow-up (N = 153), and patients with Tinea corporis/cruris applied terbinafine 1% solution or vehicle once daily for 1 week with 3 weeks of follow-up (N = 66). Efficacy was assessed mycologically and clinically at the end of treatment and throughout follow-up. In the Tinea pedis study, 66% of patients were effectively treated with terbinafine compared with 4% of the group treated by vehicle (P < .001; Mantel-Haenszel test). In the Tinea corporis/cruris study, treatment was effective in 65% of the terbinafine group compared with 8% of the vehicle group (P < .001). There were no significant differences in the frequency of cutaneous adverse events between the 2 groups in either study. We conclude that one week of therapy with terbinafine 1% solution is highly effective, superior to vehicle, and safe for use in superficial fungal infections.

  • treatment of interdigital Tinea pedis with a 4 week once daily regimen of butenafine hydrochloride 1 cream update on topical therapy for superficial fungal infections focus on butenafine
    Journal of The American Academy of Dermatology, 1997
    Co-Authors: Eduardo Tschen, Boni E. Elewski, David C. Gorsulowsky, David M. Pariser
    Abstract:

    Background: Butenafine hydrochloride, a potent new benzylamine with fungicidal activity, has been extensively studied and approved for topical use in Japan. Results reported here are from one of the first major North American butenafine clinical trials. Objective: We evaluated butenafine in the treatment of Tinea pedis in a controlled, randomized, double-blind trial. Methods: Of 80 patients with positive fungal cultures, 40 applied butenafine 1% cream and 40 applied vehicle to the affected area once daily for 4 weeks. Efficacy was assessed during treatment and 4 weeks after. Results: Significantly more patients using butenafine than using vehicle had mycologic cure (butenafine, 88%; vehicle, 33%) and effective clinical response (butenafine, 78%; vehicle, 35%). Differences between treatment groups were greatest (p<0.001) 4 weeks after treatment. Conclusion: Butenafine applied once daily for 4 weeks resulted in an effective clinical response and mycologic cure of Tinea pedis during treatment. Patients continued to improve for at least 4 weeks after treatment.

  • comparison of an antifungal agent used alone with an antifungal used with a topical steroid in inflammatory Tinea pedis
    Cutis, 1996
    Co-Authors: Boni E. Elewski, Terry M Jones, Nardo Zaias
    Abstract:

    The efficacy and safety of monotherapy with oxiconazole nitrate cream, 1 percent, a topical broadspectrum antifungal agent, were compared with those of combination therapy with oxiconazole nitrate cream, 1 percent, and fluticasone propionate cream, 0.05 percent, in a multicenter, randomized, double-blind, vehicle-controlled, parallel-group study of patients with inflammatory Tinea pedis. Both combination therapy and monotherapy were associated with significantly greater proportions of mycologic and clinical cure, and a better global response than vehicle. An unexpected finding in this study was that more than 70 percent of patients with interdigital Tinea pedis also had plantar or plantar plus vesiculobullous infection.

  • a u s epidemiologic survey of superficial fungal diseases
    Journal of The American Academy of Dermatology, 1996
    Co-Authors: Maggi E Kemna, Boni E. Elewski
    Abstract:

    Abstract Background: Large-scale studies performed outside the United States have demonstrated that most cases of onychomycosis and Tinea pedis are caused by dermatophytes, primarily Trichophyton rubrum . However, other studies have suggested that yeasts and nondermatophytic molds may play a role, particularly in onychomycosis. Objective: This study was undertaken to determine the epidemiology of superficial fungal infections in a U.S. population. Methods: Fungal cultures were performed on patients with clinically suspected Tinea cruris, Tinea corporis, Tinea capitis, Tinea pedis, and onychomycosis. Results: Dermatophytes were the most commonly isolated fungi in each type of superficial fungal disease studied. T. rubrum was the most commonly isolated dermatophyte species, although Trichophyton tonsurans was more common in Tinea capitis and equally common in Tinea corporis/Tinea cruris. In Tinea pedis and onychomycosis, dermatophytes appeared in approximately 95% and 82% of isolates, respectively. Candida albicans and nondermatophyte molds played only a minor role in onychomycosis; C. albicans was isolated in 7% of nail cultures and nondermatophytic molds were isolated in 11%. Conclusion: These results are in general agreement with other major epidemiologic studies performed outside the United States. Dermatophyte fungi cause most superficial fungal infections.

Susan Bayliss Mallory - One of the best experts on this subject based on the ideXlab platform.

  • inflammatory Tinea pedis manuum masquerading as bacterial cellulitis
    JAMA Pediatrics, 2002
    Co-Authors: Susan M. Sweeney, Karen Wiss, Susan Bayliss Mallory
    Abstract:

    Background Tinea pedis and Tinea manuum in children are more common than previously recognized. Clinical presentations of dermatophyte infections may vary in children and may be difficult to diagnose. Objective To show the necessity of potassium hydroxide preparations and/or fungal cultures in assessing suspicious cases of cellulitis in children who may have dermatophyte infections. Patients We describe 4 children with inflammatory Tinea pedis or Tinea manuum who were initially misdiagnosed as having bacterial cellulitis. Intervention A potassium hydroxide examination was performed on 3 patients. Fungal cultures were performed on 2 patients. Results Inflammatory/bullous dermatophyte infections were detected by potassium hydroxide examination in all 4 patients and all 4 children successfully responded to topical antifungal therapy. Conclusions These cases demonstrate that inflammatory tinnea pedis/manuum can masquerade as cellulitis in children. Early potassium hydroxide examination can allow appropriate antifungal treatment to be initiated before fungal culture results are finalized.

Mallory, Susan Bayliss - One of the best experts on this subject based on the ideXlab platform.

  • Inflammatory Tinea pedis/manuum masquerading as bacterial cellulitis
    'American Medical Association (AMA)', 2002
    Co-Authors: Sweeney, Susan M., Wiss Karen, Mallory, Susan Bayliss
    Abstract:

    BACKGROUND: Tinea pedis and Tinea manuum in children are more common than previously recognized. Clinical presentations of dermatophyte infections may vary in children and may be difficult to diagnose. OBJECTIVE: To show the necessity of potassium hydroxide preparations and/or fungal cultures in assessing suspicious cases of cellulitis in children who may have dermatophyte infections. PATIENTS: We describe 4 children with inflammatory Tinea pedis or Tinea manuum who were initially misdiagnosed as having bacterial cellulitis. INTERVENTION: A potassium hydroxide examination was performed on 3 patients. Fungal cultures were performed on 2 patients. RESULTS: Inflammatory/bullous dermatophyte infections were detected by potassium hydroxide examination in all 4 patients and all 4 children successfully responded to topical antifungal therapy. CONCLUSIONS: These cases demonstrate that inflammatory tinnea pedis/manuum can masquerade as cellulitis in children. Early potassium hydroxide examination can allow appropriate antifungal treatment to be initiated before fungal culture results are finalized

J Van Cutsem - One of the best experts on this subject based on the ideXlab platform.

  • double blind comparison of itraconazole with griseofulvin in the treatment of Tinea pedis and Tinea manuum doppelblind vergleich von itraconazol mit griseofulvin bei der behandlung von Tinea pedis und Tinea manuum
    Mycoses, 2009
    Co-Authors: E Van Hecke, J Van Cutsem
    Abstract:

    Summary:  One hundred and fourteen evaluable patients with Tinea pedis or Tinea manuum have been analysed in this double-blind study between itraconazole and griseofulvin. All infections were confirmed by microscopic examination and/or culture. Daily double-blind medication consisted of either 100 mg itraconazole or 500 mg ultramicronised griseofulvin and was given for 30 consecutive days. All patients were examined clinically and mycologically at the start of treatment, at the end of treatment (day 30) and 2 weeks after the end of treatment (control day 45). The clinical outcome was virtually the same for both treatment groups at the end (75% response rate for itraconazole vs. 77% for griseofulvin) and 2 weeks after the end of treatment (83% response for itraconazole vs. 82% for griseofulvin). The most important difference between both treatments was the mycological outcome, for which itraconazole showed a cure rate of 85% compared to 48% for griseofulvin 2 weeks after end of therapy (p > 0.01, Fisher's exact test). This suggests that griseofulvin treated patients are more at risk for relapse than itraconazole patients. It is concluded that itraconazole 100 mg orally once daily for 30 days is mycologically more effective than griseofulvin 500 mg once daily for 30 days in the treatment of Tinea pedis and/or Tinea manuum. Furthermore, the best results are obtained 2 weeks after the end of treatment. Clinically both treatments are equally effective. The difference in clinical and mycological results with griseofulvin may be explained by the known anti-inflammatory effect of griseofulvin. Both drugs were well tolerated and appeared to be safe for use. Zusammenfassung:  In dem vorliegenden Doppelblind-Vergleich zwischen Itraconazol und Griseofulvin wurden die auswertbaren Daten von 114 Patienten mit Tinea pedis oder Tinea manuum analysiert. Alle Infektionen waren durch mikroskopische Prufung und/oder Kultur belegt. Die tagliche Doppelblind-Medikation bestand aus entweder 100 mg Itraconazol oder 500 mg ultramikronisiertem Griseofulvin und wurde 30 Tage lang verabreicht. Alle Patienten wurden klinisch und mykologisch bei Beginn der Behandlung, bei Behandlungsende (Tag 30) und 2 Wochen nach Behandlungsende (Kontrolltag 45) untersucht. Das klinische Ergebnis war fur beide Behandlungsgruppen bei Behandlungsende (75% Ansprechquote fur Itraconazol vs. 77% fur Griseofulvin) und 2 Wochen nach Behandlungsende (83% fur Itraconazol vs. 82% fur Griseofulvin) praktisch gleich. Der wesentlichste Unterschied zwischen beiden Behandlungen war das mykologische Ergebnis. Hier ergab Itraconazol 2 Wochen nach Behandlungsende eine Heilungsquote von 85% gegenuber 48% mit Griseofulvin (p 0.01, Fisher-Test). Dies last vermuten, das Griseofulvin-Patienten ein hoheres Ruckfallrisiko als Itraconazol-Patienten haben. Die Schlusfolgerung lautet, das Itraconazol 100 mg einmal taglich p.o. uber 30 Tage mykologisch wirksamer ist als Griseofulvin 500 mg einmal taglich uber 30 Tage bei der Behandlung von Tinea pedis und/oder Tinea manuum. Dabei wurden die besten Resultate 2 Wochen nach Behandlungsende beobachtet. Klinisch waren beide Behandlungsmethoden gleich wirksam. Die Differenz zwischen dem klinischen und dem mykologischen Ergebnis mit Griseofulvin kann durch dessen bekannten antiinflammatorischen Effekt erklart werden. Beide Arzneimittel waren gut vertraglich und anwendungssicher.